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Abstract
Background: Therapeutic intervention in many neurological diseases is thwarted by the physical obstacle formed by the
blood-brain barrier (BBB) that excludes most drugs from entering the brain from the blood. Thus, identifying efficacious
modes of drug delivery to the brain remains a ‘‘holy grail’’ in molecular medicine and nanobiotechnology. Brain capillaries,
that comprise the BBB, possess an endogenous receptor that ferries an iron-transport protein, termed p97
(melanotransferrin), across the BBB. Here, we explored the hypothesis that therapeutic drugs ‘‘piggybacked’’ as conjugates
of p97 can be shuttled across the BBB for treatment of otherwise inoperable brain tumors.
Approach: Human p97 was covalently linked with the chemotherapeutic agents paclitaxel (PTAX) or adriamycin (ADR) and
followingintravenous injection,measured their penetration into brain tissue and other organs using radiolabeled and fluorescent
derivatives of the drugs. In order to establish efficacy of the conjugates, we used nude mouse models to assess p97-drug
conjugate activity towards glioma and mammary tumors growing subcutaneously compared to those growing intracranially.
Principal Findings: Bolus-injected p97-drug conjugates and unconjugated p97 traversed brain capillary endothelium within
a few minutes and accumulated to 1–2% of the injected by 24 hours. Brain delivery with p97-drug conjugates was
quantitatively 10 fold higher than with free drug controls. Furthermore, both free-ADR and p97-ADR conjugates equally
inhibited the subcutaneous growth of gliomas growing outside the brain. Evocatively, only p97-ADR conjugates
significantly prolonged the survival of animals bearing intracranial gliomas or mammary tumors when compared to similar
cumulated doses of free-ADR.
Significance: This study provides the initial proof of concept for p97 as a carrier capable of shuttling therapeutic levels of
drugs from the blood to the brain for the treatment of neurological disorders, including classes of resident and metastatic
brain tumors. It may be prudent, therefore, to consider implementation of this novel delivery platform in various clinical
settings for therapeutic intervention in acute and chronic neurological diseases.
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Introduction
Neurological diseases associated with cancers, inborn errors of
metabolism (such as lysosomal storage diseases), infectious diseases
and aging create a significant social and economic burden.
Demographics predict that, in the aging populations of the
economically developed world, the incidence of cardiovascular
disease, dementias and cancer will continue to dramatically
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2469increase over the next 20 years. Despite advances in molecular
screening technologies, which have spawned new drug targets and
therapeutic candidates for neurological diseases, these technologies
have yet to find conduits for successful clinical application due in
part to disease complexity, the individual variability within the
human population and the poor early diagnosis of disease.
However, the most serious impediment to pharmaceutical
treatment is inefficient delivery of drugs to the disease-affected
brain tissue, due to limitations and restrictions dictated by the
existence of the blood-brain barrier (BBB) [1]. Designing efficient
‘vectors’ (antibodies, protein carriers, viruses, nanoparticles) to
navigate and deliver therapeutics across the BBB in a controlled
and non-invasive manner remains one of the key goals of drug
development for brain diseases.
The BBB is found in all vertebrates and is selectively permeable.
The BBB endothelial cells are known as the ‘‘gatekeepers of the
brain’’ and the barrier is formed by the presence of high resistance
tight junctions that fuse brain capillary endothelia into a
continuous tubular cell layer separating blood from the brain. In
addition to keeping unwanted substances out, the BBB helps retain
brain-synthesized compounds, such as neurotransmitters. Fine
structural differences exist between the endothelia of the brain
capillaries and endothelia in other capillaries. These include tight
junctions between adjacent endothelial cells [2], a paucity of
pinocytotic vesicles [3,4] and a lack of fenestrations (perforations)
[5–7]. The cerebral endothelium forms tighter junctions than
other endothelia that are characterized by greater electrical
resistance and contain specific proteins, including enzymes and
transporters, whose expression appears to be augmented in
comparison to other endothelia [4,8–11]. The physiochemical
properties of the penetrating substance largely determine whether
or not it can penetrate or be transported across the BBB. In
general, small hydrophobic solutes can readily cross the BBB,
while hydrophilic substances are selectively transported across the
barrier by specific trans-endothelial membrane carrier proteins.
Thus, many substances in the blood cannot transit the BBB since
they are not compatible with the resident carrier systems.
The tightly sealed brain vasculature forming the BBB precludes
virtually all systemically injected macromolecular drug compounds
and most hydrophilic drugs from entering the brain. Furthermore,
efflux transporter proteins expressed at the BBB, such as P-
glycoprotein (Pgp1) [1], present significant problems for the
treatment of brain tumors with current chemotherapeutics [12] as
they act to pump small hydrophobic chemotherapeutic agents out
of the brain. Many methods developed to enhance the delivery of
drugs to treat brain tumors have failed to provide significant
improvements to long-term survival [13–25]. Radical methods to
transiently increase the permeability of the BBB allowing diffusion
of injected drugs into the brain [26] [27] [28] cause damage by
uncontrolled entry of the blood constituents into the brain. Thus,
specific drug design is limited by factors such as lipid solubility,
charge, molecular weight and the antiport action of specific
transporters [29,30]. A large assortment of drugs conjugated to
peptides [26,31–33], to proteins [1,31,32], or to antibodies
[28,34,35] able to bind to receptors expressed on the luminal
surface of the BBB have been investigated. MRC OX26, a
monoclonal antibody against the rat transferrin (Tf) receptor
[36,37] has been used to study transport across the BBB
[35,38,39]. Although partially effective for transport into the
brain, the use of antibodies such as MRC OX26 appears to be
limited due to saturation of the receptor with antibody, low
dissociation rate of the antibody (and indirectly its potential
payload of therapeutic compounds), and recycling of the receptor
back to the blood [40]. Furthermore, hypersensitivity resulting in
hyperimmunity against the foreign monoclonal antibody carrier
may also limit repeated treatments with the antibody-drug
conjugates. In addition, many targeted receptors are widely
expressed in other tissues resulting in potential toxicity [36,37,41].
Finally, lost in the considerable data on potential transporters,
carriers and delivery systems it is an unfortunate realization that,
at present, none of these approaches are efficacious in treating
diseases that lay beyond the BBB. Thus, novel approaches are
required to increase the survival of patients with acute and chronic
neurological diseases.
Here we have focused on the iron binding protein p97
(melanotransferrin), a protein closely related to Tf and lactoferrin
(Lf) [42]. As a result of alternative splicing, p97 exists in both a
soluble form and a cell surface GPI-linked form [43]. However, in
normal brain it appears to discretely localize on the surface of
endothelial cells and transiting through brain capillary endothe-
lium [10,44]. Studies on the structure and function of p97 suggest
it might be an ideal carrier for transport of drug conjugates into
the brain [31,33,34,37,45,46]. Recombinant p97 is actively
transported across the BBB in an in-vitro model [47] of BBB
trancytosis [48], with a transport rate 10 to 15 times higher than
that of either Tf or Lf. [48]. In addition, studies on its
biodistribution support the concept that p97 injected intravenously
preferentially distributes in brain tissue [39,49]. Furthermore, the
mechanism of transport is likely receptor-mediated transcytosis,
possibly involving a member of the low-density lipoprotein
receptor–related protein family (LRP) [49–52]. The p97 protein
exists at low serum concentrations (under 7.5 ng/mL=0.08 nM
in healthy adults) suggesting that the native protein should not
significantly block the binding of exogenously-injected p97
conjugates from reaching the receptors in the BBB. Furthermore,
the transcytosis of p97 is likely to allow piggybacked therapeutic
compounds to bypass the efflux transporter Pgp-1. Thus, based on
these collective properties, we hypothesized that p97 may be an
attractive new candidate as a drug delivery vector. Here we test
this hypothesis in a mouse model by assessing the chemothera-
peutic activity of p97-drug conjugates within the brain in
comparison with unconjugated drugs. We demonstrate that
intervention with p97-drug conjugates provides a marked
improvement over current ineffective chemotherapies for cancers
of the brain. The p97 protein, therefore, is the first carrier that
efficiently transports chemotherapeutic agents across the BBB that
therapeutically modulates disease within the brain. Thus, p97 may
have wide utility as a drug delivery vehicle for the treatment of a
variety of inoperable neurological conditions.
Methods
Cells and Animals
C6 rat glioma (ATCC CRL-2199) and ZR-75-1 human
mammary tumor (ATCC CRL-1500) cells were cultured in
DMEM supplemented with 10% heat inactivated fetal bovine
serum (FBS) at 37uCi n5 %C O 2 in air atmosphere. BHK TK
-
ts13 cells transfected with a full-length human p97 cDNA [53]
were cultured in DMEM supplemented with 10% FBS, 20 mM
HEPES, 2 mM L-glutamine, 0.08 mM zinc sulphate and 500 mM
methotrexate [53]. Soluble p97 was affinity purified as previously
described [53], its concentration determined a quantitative
antibody sandwich assay [54] and its purity determined by SDS-
PAGE analysis [54]. Female NSWNU (m) Swiss nu/nu mice aged
6–8 weeks were used for tumor models. Both male and female
C57Bl/6 mice, aged 6 to 8 weeks, were used in all other studies.
All procedures involving mice were in accordance with guidelines
set by the UBC Animal Care Committee, which states that mice
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weight or if the tumor size should exceed 5% of the animal’s
normal weight.
Microscopy
Holo-human p97, holo-human transferrin (huTf), and holo-
murine transferrin, mTf, (Sigma) were labeled with Alexa Fluor
488 (Alexa 488) protein labeling kit (Molecular Probes, MP) for
confocal microscopy or using a DIG protein labeling kit
(Boehringer-Mannheim) for electron microscopy (EM). Labeled
or unlabeled holo-proteins (0.3 mg) were injected into the tail vein.
Human Tf was used in order to allow differentiation from
endogenous murine Tf. After 1 h, mice were perfused through the
left ventricle with PBS, followed by 4% paraformaldehyde in PBS.
The brains were immediately dissected, paraffin embedded and
later sectioned. Brains were stained with either the anti-human
p97 monoclonal antibody, L235 [55] or the rabbit anti-human Tf
antibody (Research Diagnostics). Antibody binding to these tissue
sections was subsequently visualized with goat anti-mouse Ig Alexa
488 or goat anti-rabbit Ig Alexa 488 (Molecular Probes).
Fluorescent PTAX (Oregon GreenH 488 paclitaxel; Molecular
Probes) was diluted in buffer and 100 mg were injected i.v. into
each mouse. In addition, Oregon GreenH 488 was conjugated to
p97 as directed by the supplier, and 0.2 ml of the conjugate
containing 100 mg of the dye was injected i.v. Injection was
repeated 3 times during the day and mice were sacrificed by the
end of the day. Then organs were harvested and analyzed later by
fluorescent microscopy.
For electron microscopy (EM), 0.4 mg of p97 and p97-DIG
labeled with 13 nm and 5 nm gold particles (British Biocell)
respectively, were injected simultaneously into the tail vein. After
1 hr, mice were perfused and brains processed for EM [39]. Thin
sections were stained with anti-DIG antibody (British Biocell) or
visualized by gold enhancement (Nanoprobes).
Stability of
125I-p97 in Serum and Urine
Urine and serum samples were centrifuged at 90006 g for
15 min at 4uC. Samples were reconstituted in SDS-PAGE buffer
containing a final concentration of 1% SDS and were heated to
95uC for 10 min before gel separation. For reducing conditions,
2% ß-mercaptoethanol was included in the SDS-PAGE buffer.
SDS PAGE gels (12%) were run with Tris-glycine-SDS buffer and
after electrophoresis were dried and exposed to Kodak XAR Film
for 2–4 days.
Uptake of
125I-p97 into the Brain
To measure the brain uptake of
125I-p97, mice were each given
approximately 4 pmol of
125I-p97 (0.026 mg in 1.8 mCi) in 200 ml
of injection solution 14.2 mg/mouse lactated Ringer’s solution or
0.25 M phoshate buffered saline (PBS) containing 1% bovine
serum albumin (BSA) through the tail vein at time 0 with a
Hamilton syringe. After the radiolabeled p97 has been circulating
in the blood for 2 hours, organs were collected for radioactivity
measurement. The serum and brain samples were collected and
the levels of radioactivity were measured.
Multiple Regression Analysis of Entry of
125I-p97 into the
Brain
99Tc-albumin with comparable radioactivity was included in
this injection solution as a vascular marker. At 5, 10, 15, 20, 25
and 30 min after injection, blood was collected from the right
carotid artery and the mice (n=5 for each time point) were
immediately decapitated. The radioactivity in 50 ml of serum and
of weighed brain samples were measured by a dual channel c-
counter. This study provided information on the brain uptake of
125I-p97 at certain time points and further served as the control for
the concurrent investigation into whether the brain entry of
125I-
p97 was saturable. Self-inhibition of
125I-p97 brain uptake was
tested by inclusion of unlabeled p97 (1:500 and 1:1000) in the
injection mixture (7.1 mg/mouse; n=3 for each time point).
Distribution of albumin in different organs was measured in
similar fashion as the p97. To correct for the decrease of
125I-p97
concentration from blood with time, exposure time (t), which his
the integral serum radioactivity at time 0 to time t divided by the
serum radioactivity at time t [56,57], was calculated. The organ/
serum ratio of radioactivity (ml/g) was plotted against exposure
time. The slope of the linear part of this regression line represents
the influx rate, and the intercept at time 0 is the initial volume of
distribution of
125I-p97 in the organs for each group. The half-time
disappearance was determined from the regression line obtained
from the plot of the logarithm of brain radioactivity against time.
The unidirectional influx constant (Ki), expressed in ml/g-min, and
the apparent volume of distribution of the brain (Vi), in ml/g were
determined from the linear portion of the relationship between
brain/serum ratios and t with the equation; brain/serum ratio
[(cpm/g brain)/cpm/ml/g serum)]=Ki (t)+Vi.
Capillary Depletion Method to Determine the Brain
Compartmental Distribution of
125I-p97
A capillary depletion procedure [58,59] was employed to
separate the cerebral capillaries from the brain parenchyma.
Blood was collected from the carotid aorta of mice (n=5) at
60 min following the i.v. tail injection of 3.6 mCi
125I-p97.
Subsequently, the jugular veins were cut, the descending aorta was
blocked and the mice received an intracardial perfusion of
injection solution before decapitation. For each mouse, the brain
was dissected, weighed, homogenized by three passages through a
20 gauge syringe in 2 ml of 1 mg/ml collagenase/dispase. The
mixture was incubated at 37uC for 30 to 40 min and then washed
one time in PBS. The material was resuspended in 6 ml PBS and
equally split into 3 Corex tubes. Two ml of 26% dextran was
added to each tube to enable pelleting of the brain capillaries. The
samples were mixed and then centrifuged at 5400 g for 15 min at
4uC. The resulting pellet (cerebral capillaries component) and the
supernatant (brain parenchymal/interstitial fluid space) were
carefully separated and the percent contamination of the
supernatant with vasculature was assessed by measuring the
specific activity of the endothelial marker, c-glutamyl transpepti-
dase. Radioactivity of each sample was counted with a dual
channel c-counter. The ratios of radioactivity of
125I-p97 in the
supernatant (parenchyma) or pellet (capillary) over serum were
calculated, and the contamination of the vascular component was
further corrected by subtraction of the
99Tc-albumin ratios.
Synthesis and Analysis of p97-PTAX Conjugates
Conjugation of PTAX to p97 followed the procedures described
previously [60]. The MSR of p97 was determined by absorbance
analysis and was determined to be similar to transferrin, which has
a conjugate to carrier ratio of 5 PTAX molecules per p97 molecule
[60]. The stability of the conjugates in buffer and in mouse sera
was measured by HPLC at room temperature (RT) over a period
of 1 to 120 hrs.
Extraction Method for PTAX analysis
Tissue extraction was performed by a modification of the method
of Sparreboom et al.[61] and the PTAX metabolites were identified
Unique Carrier Across BBB
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Dounce homogenized, then pipetted into a glass tube and made up
to 1 ml with 4% BSA solution. Tissue samples underwent diethyl
ether extraction and solid-phase extraction (SPE). Plasma samples
consisted of 250 ml of thawed murine plasma and underwent SPE
only. Samples with less than 250 ml volume were filled up with
human citrate-phosphate-dextrose/plasma. To each sample 10 ml
of 50 mM docetaxel solution (Taxotere diluted with absolute
ethanol; Rhone-Poulenc Rorer) were added as internal standard.
HPLC analysis was performed on an Agilent HPLC apparatus. A
stainless steel(12564 mm)analytical columnequippedwitha guard
column (464 mm), both packed with 5 mm LiChrospher 100 RP-
18 material, was cooled to 33uC. The mobile phase consisted of
acetonitrile/methanol/0.2 M ammonium acetate buffer, pH 5.0,
38:10.5:51.5 (vol/vol). UV detectionwas performed at 227 nm, and
washing gradient was applied after each run (additional 35% vol/
vol acetonitrile). Injection volumes were either 50 or 100 ml. For
calibration, PTAX and docetaxel stock solutions in anhydrous
ethanol,storedat220uC,werediluted withmobilephase(1:100) on
the day of analysis. The method of analysis was validatedfor murine
plasma,brain, liver, and kidneysamples.Correlation coefficients for
PTAX calibration curves in the concentration range 50–1000 nM
were greater than 0.999. Recovery rates for PTAX ranged from 70
to 85%, depending on PTAX concentration and the type of tissue.
Brain Uptake Trials Involving p97-PTAX
Delivery of PTAX to brain was examined by the following
procedure: mice (n=10) received 5 injections of 8 mg/kg of
PTAX over one week. Before organ dissection, mice were
anesthetized (ketamine-HCl 100 mg/kg, xylazine 10 mg/kg) and
a 300 mL sample of blood removed by cardiac puncture. The left
atrium was snipped with scissors and the mouse was perfused with
heparinized saline from a peristaltic pump through a 27 gauge
needle, thereby removing all blood. PTAX concentration was
measured in brain and serum. In 5 additional mice, delivery and
stability of PTAX was measured after a single injection and the
blood concentration and stability of the conjugate (p97-PTAX)
was measured at different time points (0.25, 0.50, 1, 1.5, 2, 6 and
12 hrs; refer to Table 1) based on the free amount of PTAX
present in serum.
Synthesis and Analysis of p97-ADR Conjugates
Conjugation of ADR [(8S,10S)-10-(4-amino-5-hydroxy-6-methyl-
tetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxy-
acetyl)-1-methoxy-7,8,9,10 tetrahydrotetracene-5,12-dione] to p97
was achieved by cross-linking p97-N-succinimidyl S-acetylthioace-
tate (p97-SATA) and ADR-succinimidyl 4-[N-maleimidomethyl]-
cyclohexane-1-carboxylate (ADR-SMCC) derivatives. SATA
(Pierce Chemical Co, St. Louis MO) and the p97-SATA were
prepared according to instructions supplied by the supplier.
Activated ADR-SMCC (.96% pure) was synthesized by Albany
Molecular Research Inc. The conjugation of deacylated p97-
SATA to the activated ADR-SMCC was achieved by combining
these compounds at 4uC overnight. Conjugates (p97-ADR) were
purified on 5 mL D-Salt Excellulose (Pierce Chemical Co.)
desalting columns equilibrated with PBS. Purified p97-ADR was
assessed by SDS-PAGE, anion exchange chromatography and
Western blot analysis using the primary anti-human p97
monoclonal mouse antibody L235 [63]. Individual conjugates
were designated as SYN002, SYN018, SYN019, and SYN020.
The molecular substitution ratio (MSR) or moles of ADR bound to
moles of p97, were determined by absorbance analysis from
standard curves established for ADR and p97 at 486 and 280 nm
wavelength. The two conjugates were found to have 4 to 7
molecules of ADR per molecule of p97 at an ADR concentration of
17 to 60.6 mg/ml.
Radiolabeling of Compounds
p97, Lf, and p97-ADR conjugates were iodinated using a
standard chloramine T protocol [52]. The specific activity was
calculated from the radioactivity of the precipitable fraction after
trichloroacetic acid (TCA) precipitation. Bovine serum albumin
(BSA) in the form of
99 Tc-albumin was purchased from
Amersham (now GE Healthcare) and had a specific activity of
100 Ci/g. [
14C]-labeled ADR was purchased from Nycomed.
Stability and Quality of p97-ADR Conjugates
To determine the stability of the p97-ADR conjugate, SYN002
was prepared with [
14C]-labeled ADR. Aliquots of 200 mL were
added to 1 mL of mouse sera and incubated at 37uC. Over a
period of 18 hr, 25 mL aliquots were removed and the CPM of the
TCA-precipitable fraction was determined. The samples were run
on 12% SDS-PAGE gels as described above and protein positions
were visualized after exposure to Kodak XAR film for 25 days.
Treatment of Mice Bearing Subcutaneous Tumors
C6 glioma tumors were established subcutaneously in mice by
injecting 50 mLo f1 610
5 rat C6 glioma cells into the right flank.
Groups of 3–10 mice were treated (detailed in Table 2), starting
shortly after the tumor cells, with p97-ADR conjugate (SYN002 -
Table 1. Concentration and Stability of p97-PTAX in vitro and in vivo.
Concentration of p97-PTAX in
Buffer (ng/ml)
Concentration of p97-PTAX in Serum
After injection (nmol/kg)
Concentration of p97-PTAX in Brain After
Injection (nmol/kg)
1h r 8062.1 15 min 2.061.37 15 min 0.0660.001
5h r s 10069.1 30 min 0.660.14 30 min 0.00760.001
24 hrs 12068.4 1h 1.060.8 1h 0.0160.003
48 hrs 10067.8 1.5 h 1.560.2 1.5 h 0.01560.0002
72 hrs 8062.4 2 h 2.060.2 2 h 0.0160.004
94 hrs 3064.6 6 hrs 0.860.42 6 hrs 0.0960.006
120 hrs 1065.8 12 hrs 0.260.01 12 hrs 0.0760.003
Concentration of p97-PTAX conjugate in buffer at RT, in serum after i.v. injections and in mouse brain after i.v. injection. Free PTAX could not be detected in brain.
Sample number in buffer and serum, n=5; in brain, n=10.
+/2 are standard deviations.
doi:10.1371/journal.pone.0002469.t001
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alone by 5–10 tail vein injections (8 mL/g body mass each time)
over a period of 14–25 days for a total free or conjugated ADR at
4 mg/kg. Tumor size was monitored over 19 days. At the end of
the trial, serum was collected and analyzed for two markers of
cardiotoxicity: creatine kinase (CPK) and lactate dehydrogenase
(LDH)[64,65]. Control treatments were either PBS or ADR alone.
Treatment of Mice Bearing Intracranial Tumors
Mice were anaesthetized with ketamine (100 mg/kg) and
xylazine (10 mg/kg). A motorized injector delivered 4610
5 C6
glioma or 1610
6 ZR-75-1 cells in 5 mL PBS at rate of 1 mL/min
from a 25 mL Hamilton syringe through a 27 gauge needle to a
position located 3 mm below the surface of the skull, 3 mm in
front of coronal suture and 3 mm to the right of midline. The
needle was removed slowly two minutes after the completion of the
injection. The site was wiped with an alcohol soaked swab and
sealed using sterile bone wax, and the scalp incision closed with
sterile clips. Mice bearing intracranial C6 glioma were treated with
repeated injections (8 mL/g body mass - jugular vein) of p97-ADR
(SYN002 - 0.06875 mg/ml ADR) for a total dose of 5.5 mg/kg
ADR, or free ADR (0.5 mg/ml ADR in PBS) for a total dose of
20 mg/kg, or PBS alone.
In Trial 2, the effectiveness of SYN002 conjugate against
intracranial ZR-5-1 mammary tumors was assessed by repeated
tail vein injections of 8 mL per g body weight solutions containing
PBS, ADR (0.25 mg/ml ADR in PBS) or SYN002 (0.06875 mg/
ml ADR). The dosing regime is outlined in Table 2 and carried
out over a period of 15 days to a total of 20 mg/kg free ADR or
5.5 mg/kg conjugated ADR. Survival was reported as the
percentage of total mice receiving an intracranial tumor. The
data were represented as Kaplan-Meier survival curves. Mean and
median survival in days since tumor implantation were calculated
for each treatment. Efficacy of the conjugate and free ADR were
determined as a percent increase of mouse survival time as
compared to mice given PBS as control.
Brain Uptake Trials Involving p97-ADR
Mice received tail vein injections of
125I-p97-ADR conjugates
(SYN019, SYN020),
125I-p97,
125I-BSA, or
125I-Lf (8 ml/g body
mass, 3 mg protein/ml). One hour after injection, mice were
anesthetized (ketamine-HCl 100 mg/kg, xylazine 10 mg/kg) and
a 300 mL sample of blood removed by cardiac puncture. The left
atrium was snipped with scissors and the mouse was perfused with
heparinized saline from a peristaltic pump through a 27 gauge
needle. After perfusion, the brain was removed and CPM per
gram of tissue determined using a Gamma counter (CobraII,
Packard, IL).
Statistical Analysis
Means are reported with their standard errors. Groups were
compared by one-way analysis of variance (ANOVA) followed by
Duncan’s multiple or Tukey’s range test. For regression analysis,
the least squares method was used, as well as the difference
between the slopes of regression lines.
Results
Study design
The biodistribution of intravenously injected p97 vector, free
drug, or p97-drug conjugates were examined initially. The
modulation of growth of representative classes of tumors growing
in peripheral tissues outside the BBB (subcutaneously) and growing
cloistered behind the BBB (intracranially) were examined including
resident(rat C6)gliomaand metastatic(humanZR-25-1) mammary
tumor cells. Both tumor types present with reliable characteristic of
growth, which parallels patterns witnessed in the equivalent diseases
in humans. They both have 100% take rates in nude mice and
reproducibility in survival patterns [66,67]. We chose to examine
the therapeutic effects of ADR and p97-ADR conjugates rather
than PTAX and p97-PTAX because C6 is resistant to the cytostatic
activity of PTAX [68]. We recorded tumor size and mouse
mortality in groups of nude mice inoculated either subcutaneously
Table 2. Injection Schedule of ADR-conjugates in Different Mouse Models.
Trial n Tumour Cell type Tumour location Treatment Injection schedule (Day) Total ADR (mg/kg)
1 9 C6 Subcutaneous PBS 3,4,5,6,10,11,12,13 (8) 0
9 C6 Subcutaneous ADR 3,4,5,6,10,11,12,13 (8) 4
9 C6 Subcutaneous SYN002 3,4,5,6,10,11,12,13 (8) 4
2 10 ZR-75-1 Intracranial PBS 3,4,5,6,7,10,11,12,13,14 (10) 0
10 ZR-75-1 Intracranial ADR 3,4,5,6,7,10,11,12,13,14 (10) 20
10 ZR-75-1 Intracranial SYN002 3,4,5,6,7,10,11,12,13,14 (10) 5.5
3 10 C6 Intracranial PBS 1,3,7,10,14 (5) 0
10 C6 Intracranial SYN018 1,3,7,10,14 (5) 0.49
4 10 C6 Intracranial PBS 2,9,17,20,25 (5) 0
10 C6 Intracranial ADR 2,9,17,20,25 (5) 20
10 C6 Intracranial SYN002 2,9,17,20,25 (5) 2.75
5 2 N/A N/A BSA (1) 0
2 N/A N/A Lf (1) 0
5 N/A N/A p97 (1) 0
3 N/A N/A SYN019 (1) 0.1
3 N/A N/A SYN020 (1) 0.1
Injection schedule indicates the number days after the tumor implant when the single injections of the specific treatments were administered. The number in the
brackets indicates the total number of injections. All injections were i.v. made via the tail vein with the exception of Trial 4, which used intra-jugular injections.
doi:10.1371/journal.pone.0002469.t002
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(rat glioma and human mammary tumors) which were then treated
with p97-ADR, free drug or saline controls.
Stability and Biodistribution of p97
The stability of iodinated p97 was verified at room temperature
in buffer and in serum samples taken at different time points after
injection. Plasma analysed by SDS-PAGE at 1 hour post-i.v.
injection showed the great majority of
125I remained at the p97
MW position (Figure 1a). Its appearance in urine was accompa-
nied by a proteolytic cleavage event (Figure 1). One hour after
injection,
125I-p97 levels in the blood, kidney, bladder, liver,
spleen, gallbladder, eye, heart and lung were all higher than in the
central nervous system (Figure 2a). The initial uptake of p97 in the
kidney, liver and spleen increased rapidly within minutes of
injection and then decreased within the subsequent few hours.
After 1 hr, p97 was found to accumulate in the brain while its level
in all other organs decreased. The decrease in p97 concentration
in plasma over time is shown in Figure 2b, whereas 10 minutes
after injection of iodinated p97, it begins to accumulate in the
brain (Figure 2c). After 6 h, the majority of
125I-p97 associated
with the brain was localized to the brain parenchyma (83%), and
not the blood vessels (Figure 3). Unlike the other organs, the brain
continued to accumulate p97 at 24 hours after injection. After
24 hrs, the total accumulation of p97 in the brain reached 1–2%
of the injected dose.
Entry of p97 into the Brain via a Receptor-Mediated
Process
Supporting the hypothesis that p97 enters the brain through a
receptor-mediated process on the BBB, we have found that the rate
of uptake into the brain of i.v. injected
125I-p97 can be inhibited in a
dose related manner by an excess of unlabeled p97 (Figure 4),
supporting previously published data [52]. This ‘‘cold block’’
signifies competition for a receptor to the point of saturation.
Competition with an excess of nonradiolabeled p97 in other organs
such as the liver, kidneys and lungs is very low (data not shown),
suggesting that p97 is not taken up in these organs in a receptor-
mediated fashion. It also suggests that the brain expresses a higher
concentration of receptors for p97 than these other organs. Using
multiple-time regression analysis [57,69] we found that the influx
constant (Ki) is higher for p97 (Figure 4) than that for albumin [70],
which crosses the BBB through extracellular pathways, again
suggesting the presence of a receptor mediated system of
125I-p97
transport. The entry of
125I-p97 into brain, measured by the brain/
serum ratios of radioactivity (ml/g), was linear when plotted against
exposure time. A dose-related self-inhibition of the Ki for
125I-p97
brain uptake was achieved by co-administrating an excess of
unlabeled p97 protein. The brain influx rate (Ki) for each group is as
follows: (a)
125I-p97 only: 2.0260.28 ml/g-min; (b)
125I-p97 plus
12 mg of p97: 0.4560.08 ml/g-min; and (c)
125I-p97 plus 15 mg of
p97: 0.1660.19 ml/g-min. The difference in the regression lines
slopes was statistically significant [F(2,17)=21.8, P,0.0001]. The
finding that the entry of p97 into the brain can be significantly
inhibitedbyunlabelledp97suggeststhatthismayinvolveareceptor-
mediated process. The addition of unlabeled p97 did not change the
entry rate for
99Tc-albumin (overall Ki=20.160.03 ml/g-min).
Microscopic Visualization of p97-Conjugates in the Brain
Drug carriers that efficiently piggyback drugs into the brain
after peripheral administration would be expected to first localize
to the brain then rapidly translocate within the parenchyma, and
then perhaps eventually emerge in the cerebrospinal fluid. Thus
we examined if (i) fluorescence-labeled conjugates of p97 or (ii)
unlabeled could efficiently traverse the BBB and appear in the
parenchyma of the brain. One hour after i.v. injection, p97-Alexa
488 conjugate (Figure 5a) and p97 (Figure 5c) could be seen both
in the lumen of brain microvasculature and within cortical cells by
fluorescence microscopy. Fluorescence in cortical cells exhibited a
punctuate distribution in the cytoplasm but not in the cellular
processes. This staining pattern was in contrast to fluorescence
associated with Tf-Alexa 488 (Figure 5b) and Tf (Figure 5d).
Punctate cytoplasmic staining in cortical cells was not observed for
Tf-Alexa 488 or Tf, despite strong staining in the microvasculature
similar to that observed for p97. This is consistent with previous
observations that p97 can effectively traverse the BBB. The
integrity of the BBB following i.v. injection of p97-DIG conjugate
(Figure 5e) was examined using EM. Specific staining for p97-DIG
was observed in the brain parenchyma abluminal to the
microvasculature. Despite weak fixation, the BBB was demon-
strated to be intact, indicating that p97-DIG crossed into the brain
without disruption of the BBB. Furthermore, p97-PTAX was
clearly identified in brain parenchyma (Figure 5f), whereas free
PTAX could not be seen in brain but was visualized in other
organs such as heart and liver (not shown). These data indicate
that p97 can transport a wide variety of molecular compounds
across the BBB and that the drugs conjugates remain intact
following delivery to the brain.
Stability and Biodistribution of ADR and PTAX
Conjugates
The stability of p97-PTAX conjugate was verified in buffer and
in serum samples at ambient (room) temperature, taken at
different time points after injection by SDS-PAGE analysis and
HPLC analysis. As determined by HPLC analysis, the conjugate
stored in buffer was stable for over 24 hrs at room temperature
Figure 1. Stability of p97 in the mouse 1 hr. after intravenous
injection. Iodinated p97 protein is found intact in plasma after 1 h
post-i.v. injection, but appears to undergo a cleavage event prior to
appearance in urine.
doi:10.1371/journal.pone.0002469.g001
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conjugate (Figure 5f) and its metabolites were detected in brain
tissue but free PTAX was not detected in the brain (Table 1).
The stability of the p97-ADR conjugates was directly assessed
by analyzing tissues and body fluids post injection. p97-[
14C]ADR
conjugate was stable in mouse serum for at least 1 h, with some
degradation observed after 18 h (Figure 6a). Protein-associated
radioactivity after TCA precipitation remained above 80% for the
duration of the experiment. The MSR for the p97-ADR
conjugates ranged between 5 and 6. The brain uptake of
125I-
p97 and
125I-p97-ADR was compared to
125I-BSA and
125I-Lf one
hour after a single bolus tail vein injection (Figure 6b). Uptake of
125I-p97 and
125I-p97-ADR conjugates (SYN019 and SYN020)
into the brain were almost ten-fold higher than that of BSA or Lf.
These data show that conjugation of ADR to p97 does not affect
the transport of p97 into the brain.
Effect of p97-ADR Conjugate on Subcutaneous Tumors
Treatment of C6 gliomas grown subcutaneously in mice was
performed with both p97-ADR conjugate (SYN002) and free
ADR. Both significantly (p,0.01* ANOVA) inhibited tumor
growth by over 50% during a 20 day period when compared to
PBS treatment (Figure 7a). The ADR doses (4 mg/kg, total) used
Figure 2. Distribution of p97 in tissues and organs after intravenous injection. (a) Tissue plasma ratios of iodinated p97, normalized by
organ mass, in a variety of organs at one hour post-injection, including: whole brain, spinal cord, eye, heart, lung, liver, gall bladder, spleen, kidney,
blood, bladder, and tail, n=5 mice. (b) The plasma concentration radioactivity, normalized by plasma mass, of
125I-p97 after i.v. injection decreases
over time. The figure represents data from one mouse. (c) The radioactivity, normalized by plasma mass concentration, of
125I-p97 after i.v. injection
increases in brain over time. The figure represents data from one mouse at each time point.
doi:10.1371/journal.pone.0002469.g002
Figure 3. Intravenously injected p97 is able to cross the BBB
and enter the brain. At 6 h post-injection greater than 80% of the
p97 in the brain is found in the parenchyma rather than the capillary
blood vessels.
doi:10.1371/journal.pone.0002469.g003
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(10–15 mg/kg). The SYN002 conjugate was slightly more effective
than treatment with an equivalent amount of pure ADR.
Effect of p97-ADR Conjugation on Cardiotoxicity
There were significant differences in the serum levels of the two
markers of cardiac damage, LDH and CPK after treatment of the
animals (Figure 7b), as measured at the end of the trial (day 20).
Treatment with ADR alone increased the level of both of these
markers by over three-fold. Treatment with an equivalent amount
of ADR conjugated to p97 (SYN002) had little effect on the level
of these markers of cardiac cell damage, implying that conjugating
ADR to p97 may reduce the cardiotoxic effects of ADR treatment.
In all trials, the body weight of the mice did not appear to be
affected by the treatments when compared to PBS controls.
Efficacy of p97-ADR Conjugates on Intracranial Tumors
The dosing schedules and different trials are outlined in Table 2,
while the results of the treatments are presented in Table 3. In
Trial 2 (Figure 8a) where the mice with intracranial ZR-75-1
mammary tumors were treated with p97-ADR SYN002 via tail
vein injections, mean and median survival times were increased by
77% and 20.8% compared to the PBS treated group. It is
interesting that treatment with free ADR alone appeared to
reduced the mean and median survival of the mice suggesting
greater global organ and tissue toxicity due to free ADR in these
mice. It should also be noted that the total ADR injected in the
form of conjugate was four times less than that of free ADR. A
higher dosage of p97-ADR might further increase survival rates.
Two mice in the SYN002 treated group survived to 50 days and
were reported, after autopsy, to be tumor-free survivors. In Trial 3
(Figure 8b) where mice with intracranial C6 gliomas were treated
with SYN018 via tail vein injections, mean and median survival
times were increased by 40% and 44% respectively compared to
the PBS treated group. The efficacy of the p97-ADR conjugates,
SYN002 and SYN018, did not appear to be affected by differences
in the preparation and both were effective in the treatment of
tumors. Significant increases in survival time were again achieved
with relatively small total doses of ADR borne as p97-ADR. In
Trial 4 where mice with intracranial C6 gliomas were treated with
SYN002 via intrajugular vein injections, mean and median
survival times were increased by 28% and 35% respectively when
compared to the PBS treated group. In this trial, treatment with
free ADR also improved the mean and median survival times of
the mice but the improvement was considerably less than that of
Figure 4. Multiple time
-regression analysis of the rate of p97
entry into the brain. The entry of
125I-p97 into the brain, measured
by the brain/serum ratios of radioactivity (ml/g), was linear when plotted
against exposure time. Addition of unlabeled p97 dose responsively
inhibited the entry of the radiolabeled
125I p97 protein. The influx rate
(Ki) for each group was found to be as follows: (i)
125I-p97 only:
2.0260.28 ml/g-min; (ii)
125 I-p97 (plus 12 mg of cold p97):
0.4560.08 ml/g-min; and (iii)
125I-p97 (plus15 mgo fc o l dp 9 7 ) :
0.1660.19 ml/g-min. The difference among the slopes of the regression
lines was statistically significant, p,0.0001. The graph represents one
mouse.
doi:10.1371/journal.pone.0002469.g004
Figure 5. Visualization of p97 and Tf uptake in the brain. (a)
Alexa 488 labeled holo-p97 and (b) Alexa 488-holo-Tf appear in the
brain after one hr following injection in mice. Although p97 and Tf can
be seen in the microvessels of respective mice (solid arrows), p97
appears to transcytose the BBB more efficiently than Tf and exhibits a
punctate distribution in the cytoplasm of cerebral cortical cells (open
arrows). Immunohistochemistry of (c) holo-p97 and (d) holo-Tf in the
brain one hr after intravenous injection, using respective antibodies,
show that although the two proteins are seen in the microvessels of
respective mice (solid arrows), p97 appears to transcytose the BBB more
efficiently than Tf and exhibits a punctuate distribution in the brain
parenchyma (open arrows). Scale bar represents 5 mm. (e) After DIG-
labeled p97 was injected into a mouse, the brain was harvested,
sectioned, and the p97 localized with colloidal gold conjugated anti-
DIG antibody and visualized by gold enhancement. Although paren-
chymal structures are weakly fixed, this EM shows that DIG conjugated
p97 crosses the intact BBB and can be seen in the brain parenchyma. (f)
Fluorescent PTAX is clearly shown within hipocampal brain sections of
mice after the 5
th injection (solid arrows).
doi:10.1371/journal.pone.0002469.g005
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the mice. Compared to Trial 2, efficacy of the p97-ADR did not
appear to be affected by injection method, either tail vein or
intrajugular vein. Therefore, the three studies showed that
treatment with the p97-ADR conjugates were able to significantly
extend the survival of mice with intracranial C6 gliomas or ZR-75-
1 mammary tumors.
Discussion
The present study describes the first protein based ‘ferrying’
system that can be used as a brain delivery vehicle for traversing
therapeutically efficacious concentrations of drugs into the brain
for the treatment of neurological disease.
We have demonstrated that recombinant human p97, injected
into experimental mice, showed few signs of molecular breakdown
in circulating blood, even after 8 hours. In time-course studies, we
showed that 10 minutes after the injection of radio-iodinated p97,
more radioactivity was detected in the brain than after injection of
radio-labeled albumin control. One hour after injection,
125I-p97
radioactivity, normalized per mg of tissue wet weight, in the blood,
kidney, bladder, liver, spleen, gallbladder, eye, heart and lung
were all higher than in the central nervous system. The initial
uptake of p97 in the kidney, liver and spleen increased rapidly
within minutes of injection. However, after 1 hr, p97 was found to
accumulate in the brain while its uptake in all other organs fell to
the same level as the albumin control. Unlike the other organs, the
brain continued to accumulate p97, even 24 hours post injection.
Over this 24 hr period, the ratio of counts per minute per mg due
to
125I-p97 in the brain compared to that in the plasma reached
10:1. After 24 hr, the total accumulation of p97 in the brain
reached 1–2% of the injected dose equivalent to the ratio of brain
to body weight-the first carrier system to approximate this
biological feat. This is a much higher accumulation than that
others have observed for chemotherapeutics to date [15,71,72].
For example, less than 0.1% of morphine accumulates in the brain
over time[73]. The organ distribution of
125I-p97, its brain
accumulation over time and the fact that the BBB microvascu-
lature lacks albumin receptors suggests that
125I-p97 entry into the
brain is likely due to a receptor. Accumulation of homologous
(murine) p97 would possibly be even greater than of the
Figure 6. The stability and distribution of p97 and p97-
conjugates in the brain of mice. (a) p97-ADR[
14C] appears to be
stable in mouse serum over time. Lanes. 1=0 (minutes) and 90% (TCA
precipitable counts), 2=10 min/92%, 3=20min/94.7%, 4=30min/
90.5%, 5=40min/83.9%, 6=60min/93.9%, and 7=18 hours/83.3%.
The position of the [
14C] molecular weight markers are as indicated.
(b) A comparison of protein and protein conjugates crossing the BBB in
mice 1 h after tail vein injection. CPM per g of brain tissue as a
percentage of the total CPM injected. The albumin (BSA) (n=2) and
lactoferrin (Lf ) (n=2) show low levels while p97 (n=5) and both p97-
ADR conjugates SYN019 (n=3) and SYN020 (n=3) are significantly
higher at one hour post injection.
doi:10.1371/journal.pone.0002469.g006
Figure 7. Mice bearing subcutaneous tumors were treated with
p97-ADR conjugates. a) Tumor growth of subcutaneous C6 glioma
mass in mice treated with p97-ADR conjugate SYN002 (4 mg/kg ADR, s-
s), ADR (4 mg/kg, n-n) or PBS (l-l). Arrows indicate injection schedule
(also refer to Trial 1 in Table 1). (n=9 for each treatment group) b)
Activity of LDH and CPK in serum from mice treated with the p97-ADR
conjugate SYN002 (4 mg/kg ADR), ADR alone (4 mg/kg) or PBS. Values
represent mean values+standard deviation (n=3).
doi:10.1371/journal.pone.0002469.g007
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transfer of this technology into a clinical application in humans. In
the present study, the transport of p97 across the BBB without
altering BBB permeability was confirmed using microscopy
(Figure 5). The uptake of Alexa-, DIG- or gold-conjugated-p97
and unconjugated p97 by the brain was observed using confocal
microscopy and EM (Figure 5). Consistent with studies using
radio-labeled compounds [39], the BBB appeared to be more
effective in limiting the entry of Tf into the brain than p97. The
distribution of Tf was limited to microvessels, whereas p97 was
observed in the cerebral parenchyma (Figure 5).
To determine whether p97 completely traverses the BBB or still
resides within the circulation (mainly capillaries), the compart-
mental distribution of
125I-p97 after i.v. injection was analyzed by
applying the capillary depletion method to the cerebral cortex. As
the BBB isolates the cortex from all systemic influences, any
systemically i.v. administered
125I-p97 recovered from the brain
parenchyma must have penetrated the BBB from the circulation.
Six hours after i.v. injection into mice, we found most
125I-p97
(over 80%) associated with the brain parenchyma rather than in
the brain capillaries. The fluorescence distribution (Figure 5)
makes it unlikely that p97 is attached to the luminal surface of the
endothelial walls. These results indicate that
125I-p97 does not
associate with the CNS vasculature but is transcytosed through the
endothelial cells into the brain parenchyma, consistent with past
findings [10,44,74].
Supporting the hypothesis that p97 enters the brain through a
receptor-mediated process on the BBB, we have found that the
rate of uptake into the brain of i.v. injected
125I-p97 can be
inhibited in a dose related manner by an excess of unlabeled p97
[52]. This ‘‘cold block’’ signifies competition for a receptor,
possibly a LRP receptor [52]. Using multiple-time regression
analysis [57,69] we found that the influx constant is higher for p97
(Figure 4) than that for albumin, which crosses the BBB through
extracellular pathways [70], again suggesting the presence of a
receptor mediated system of
125I-p97 transport, as suggested in
previous reports [49,74]. In contrast, the addition of unlabeled p97
did not change the entry rate of
99Tc-albumin indicating that there
was no disruption of the BBB due to injection of these radiolabeled
proteins. We have also shown that PTAX-conjugated-p97 is
transported to the brain (Figure 5f), whereas free PTAX could not
be detected. We were able to identify PTAX and its metabolites in
mouse brains after a cycle of 5 injections of p97-PTAX (Table 1).
Standard clinical chemotherapy for brain tumors includes
highly lipophilic alkylating agents such as nitrosourea and
temozolomide [72] which are able to cross the BBB. However,
their effectiveness is limited by the low sensitivity of primary
tumors to these drugs [75]. As a rigorous test of p97 as a drug
delivery agent, we chose to use anti-cancer drugs with a high
Figure 8. Mice bearing intracranial tumors were treated with
p97-ADR conjugates. a) Percentage (%) survival of mice bearing
intracranial ZR-75-1 mammary tumors and treated with p97-ADR
conjugate SYN002 (5.5 mg/kg ADR, s-s), ADR (20 mg/kg, n-n) or PBS
(l-l). b) Percentage (%) survival of mice bearing intracranial C6 glioma
tumors and treated with p97-ADR conjugate SYN018 (0.49 mg/kg ADR,
s-s) or PBS (l-l).
doi:10.1371/journal.pone.0002469.g008
Table 3. p97-conjugated ADR increased survival times in mice with intracranial tumors.
Trial Compound
Mean Survival
In Days
% Change in Mean
Survival
% Change in
Median Survival
Log Rank
Significance
2 (Zr-75-1 Tumors) PBS 10 - - -
ADR 9.24 27.6 212.5 p,0.05
SYN002 17.7 77 20.8 p,0.005
3 (C6 Tumors) PBS 20.2 - - -
SYN018 28.3 40 44 p,0.001
4 (C6 Tumors) PBS 21.8 - - -
ADR 24.13 10.7 13.6 p,0.05
SYN002 27.9 28 35 p,0.005
The percent increase in survival times for mice with free or conjugated ADR compared to controls treated with PBS clearly indicates that ADR conjugation to p97 results
in a survival advantage for mice with intracranial tumors.
doi:10.1371/journal.pone.0002469.t003
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normally blocked by the BBB. Thus we chose to study Paclitaxel
(PTAX) and Doxorubicin (formerly Adriamycin (ADR)). PTAX
was first identified in the bark of the Pacific yew tree, Taxus
brevifolia, by Monroe E. Wall and Mansukh C. Wani [76]. Initially,
there were concerns regarding potential environmental impact
when it was learned that 1,200 kg of pacific yew tree bark yielded
only 10 g of pure material [77]. In order to address this problem,
Pierre Potier and then Robert A. Holton, completed the first semi-
synthesis of PTAX from the needles of the English yew tree, Taxus
baccata [77]. This was followed by the first total synthesis of PTAX
by Holton and his colleagues [78,79]. Subsequently, fermentation
techniques were developed to allow large scale production without
invoking wide-scale decimation of Pacific or European Yew
populations [80]. PTAX blocks cell division by binding and
stabilizing microtubules, which comprise the cytoskeleton and the
mitotic spindle [81]. It is used in the treatment of lung, ovarian,
breast, head and neck cancers and advanced forms of Kaposi’s
sarcoma [77]. Unfortunately, PTAX has no beneficial clinical
effect in halting the growth of brain tumors or extending the life of
patients with brain tumors largely due to its inability to traverse
the BBB [82,83]. We find that while p97-PTAX conjugates
effectively cross the BBB, we chose to study the therapeutic effects
of ADR because PTAX lacks tumorcidal or cytostatic activity
against C6 gliomas [68].
Another common chemotherapeutic agent studied here, ADR,
is an anthracycline glycoside. It was derived from a red-colored
antibiotic produced from a strain of Streptomyces peucetius by a group
at Farmitalia Research Laboratories working near the shores of
the Adriatic Sea [84]. ADR is commonly used to treat leukemias,
Hodgkin’s lymphoma as well as solid tumors such as cancers of the
breast, stomach, bladder, lung, ovaries, thyroid and soft tissue
sarcomas, multiple myeloma, and others [85]. It has a number of
possible mechanisms of action, including inhibition of DNA
replication after it intercalates with DNA. ADR inhibits the
progression of the enzyme topoisomerase II after it has broken the
DNA chain to allow replication; it prevents the DNA double helix
from being religated [86,87]. ADR is 500–3000 times more
effective against glioma cells in vitro [88] than in vivo, but the
presence of efflux pumps localized at the blood–brain barrier
renders it ineffective against tumors in the CNS [12,89]. In
addition, its effectiveness is limited by a short half-life in vivo,a
large apparent volume of distribution that results in low brain
tumor accumulation [90] and toxic side effects on normal organs,
including the heart [91]. Therefore, in the chemotherapeutic trials
conducted here, ADR conjugates were particularly good candi-
dates for evaluation because free ADR is excluded from the brain
by Pgp1 efflux activity and because ADR is completely ineffective
in treating brain tumors [92] because of hindrance by the BBB.
The p97-ADR conjugates were stable in serum (.18 hours) and
two different batches had very similar properties. In all the trials,
the total dose of conjugated ADR injected into mice was
significantly lower than that of a typical therapeutic dose of free
ADR (see Table 2). In Trial 1, we showed that p97-ADR
(SYN002) was as effective in inhibiting subcutaneous glioma tumor
growth as an equivalent amount of free ADR (over 50% reduction
in tumor mass over a period of 19 days) (Figure 7a). The data
further demonstrated that therapeutic amounts of ADR [30],
could be delivered into the brain upon conjugation to p97. In Trial
5 (Table 2 and Figure 6b), we showed that similar amounts of p97
as p97-ADR conjugates (SYN019 and SYN020) were transported
into the brains of mice after tail vein injection. Both were
transported into the brain at significantly higher levels (approx-
imately 10 fold higher) than lactoferrin control [48].
Free ADR has been shown to be cardiotoxic in some cases
[64,65] and it can cause neuro-toxicity when administered to the
brain via partial permeabilisation of the BBB [93], limiting the
amount of ADR tolerated by human patients. In Trial 1, two
enzyme markers of cardiotoxicity, LDH and CPK, were monitored.
When free ADR was administered, there was a significant increase
in both markers. In contrast, when p97-ADR was administered, the
levels of both markers were similar to that seen after PBS injections,
indicating that conjugation to p97 could reduce the toxic effects of
ADR in future clinical settings. It has been noted by others [33] that
ADR cardiotoxicity can be reduced by conjugation of ADR to the
peptides D-penetratin and SynB1. In addition, delivery of ADR via
liposomes has resulted in reduced cardiotoxic effects [92]. It is not
clear, whether conjugation or delivery by liposomes reduces the
cardiotoxic effects of ADR by altering biodistributionor limiting the
entry of ADR into cardiac tissue.
In the intracranial trials (Trials 2–4), treatment at 1 to 3 day
intervals with the p97-ADR conjugates resulted in significant
prolongation of survival of mice with brain tumors when
compared to treatment with ADR alone. In Trial 2, mice bearing
ZR-75-1 mammary tumor cells were treated, starting the next day,
with the p97-ADR conjugate, SYN002. Untreated, the average
mouse survival time was only approximately 10 days. Treatment
with the conjugate raised mean and median survivals to 77% and
20% respectively. Notably, two mice out of the 10 in the treatment
group survived for over 50 days and were tumor-free at autopsy,
by careful gross (non-histological) inspection. In trials 3 and 4,
mice were injected intracranially with rat C6 glioma cells and
treated with the p97-ADR conjugates SYN002 and SYN018
either via tail vein injection (Trial 3) or via intra-jugular injections
(Trial 4). These brain tumors grew slower than ZR-75-1 tumors
resulting in an average survival time of 21 days for untreated
animals [67,94]. In both trials, significant increases in mean and
median survival were achieved with p97-ADR (Table 3). In Trial
3, p97-ADR treatment allowed the mice to live more than 8 days
longer than PBS control-treated animals, resulting in a 40%
increase in mean survival and a 44% increase in median survival
over PBS controls. In Trial 4, also found that p97-ADR treatment
allowed the tumor-bearing mice to live 8 days longer than PBS
controls and 4 days longer than mice treated with free ADR. This
worked out to a 28% increase in mean survival (35% increase in
medial survival) over PBS, and a 16% increase in mean survival
over free ADR. In other studies (not shown), treatment with p97
alone had no effect on tumor suppression. The total ADR injected
into mice over a given trial was significantly less than a typical
human clinical therapeutic dose administered as a single bolus
(20 mg/kg or 60 mg/m
2 versus 23.2 mg/kg or 70 mg/m
2)
[95,96]. Therefore, future trials will test whether higher total
ADR dosage, delivered as p97 conjugates, will further increase
survival times. Nevertheless, these studies demonstrate that p97,
once conjugated to drug compounds, can cross the blood brain
barrier at a similar rate to its normal (unconjugated) physiological
efficiency and that the molecule remains intact following
transcytosis but its payload is fully tumoricidally active once
placed inside the brain and behind the BBB.
The presence of the BBB, although protective in design, not
surprisingly limits the effectiveness of therapeutic drugs directed at
the treatment of diseases of the brain. The BBB effectively
prevents most drugs from reaching the brain, whether or not they
are intravenously injected. Situations where this becomes most
evident are during therapeutic applications such as treatment of
neurophysiologic disorders (including lysosomal storage diseases),
brain cancers (neuroblastomas, gliomas), infections and inflam-
mation, trauma, and delivery of constructs used for gene therapy.
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transcellular pathway (crossing through individual endothelial
cells), the paracellular pathway (crossing between adjacent
endothelial cells), intrathecal injection into the space surrounding
the spinal cord or intracerebral injection (mechanical disruption of
BBB by needle). Certain molecules may passively diffuse through a
lipid membrane, employing the transcellular route. Increased lipid
solubility, lack of polarizability, changes in hydrogen bonding
ability and molecular size may make this route possible. Generally,
the more lipid-soluble a molecule is, the more readily it moves
from the aqueous environment of the blood across the nonpolar
(lipid) environment of the endothelial cell membrane and enters
the brain [97]. Counteracting influences that may slow diffusion
include pH, temperature (unlikely to be of pharmacological
importance in the mammalian brain) and retention in the blood
due to protein binding [97]. Molar excess refraction, or the
approximate measure of total volume, also appears plays a role in
passive diffusion since diffusion coefficients are inversely related to
molecular size, such that smaller compounds diffuse faster than
larger compounds. Interestingly, permeability across the BBB
appears to be inversely correlated to molecular size, where the
addition of nonpolar groups to smaller molecules actually increases
their ability to cross lipid barriers [97]. The disadvantage is that
with this method, increased penetration across all membranes, not
only the BBB, is increased non-specifically.
Another general route for transfer into tissues is the paracellular
route, between capillary endothelial cells in this case. However, in
the BBB, the paracellular route is blocked by tight junctions,
preventing diffusion of even small molecules such as ions and
water. Temporary deliberate disruption of this barrier to deliver
drugs may be achieved by intravenous injections of hyperosmotic
solutions (i.e. 2M mannitol) [98–100] or of biologically active
agents such as bradykinin or angiotensins [97,101]. However, the
permeabilisation effects are neither confined to the brain, so there
is no drug tissue-selectivity; nor are they molecularly selective
within the brain. Ionic/chemical imbalances ensue, and plasma
proteins can not find their way into the brain extracellular fluid.
Osmotic shock is therefore bound to be harmful due to the non-
specificity of the proteins and other molecules which may also
enter the brain extracellular fluid along with the drug of choice.
Highly active efflux systems also limit the passive diffusion of
molecules across the BBB. Three families of large glycosylated
membrane proteins that act at the BBB include Pgp1, multi-drug
resistant proteins (MRP1 and MRP5), and organic anion
transporting polypeptides (OAT3 and OATP1) [97,102]. All
exhibit broad substrate specificity. Some progress is being made in
animal models to identify compounds that temporarily inhibit
efflux pumps while momentarily allowing normally excluded
therapeutic compounds to enter the brain[103], though the
apparent draw back appears to be unforeseen dose related toxicity.
Currently, direct intra-cerebral delivery (infusion or implanta-
tion) is the only effective brain treatment to allow increased drug
delivery [101,104] that was previously described. However, the
volume that can be delivered is limited (as compared to
intravenous injection), and the drug must still diffuse to the brain
parenchyma from the site of deposit to be effective. A high risk of
infection and high neurosurgical costs are also involved in this
approach. Other procedures for brain delivery, including delivery
of microcapsulated drugs [105–107], and the exploitation of
specific membrane transporters for conjugated drugs are being
investigated. Furthermore, it has been found that antibodies
conjugated to drugs, can cross the BBB as a result of their
interaction with specific receptors, which suggests that such
conjugates may be of value in the delivery of systemic-borne
therapeutic agents to the brain [31,107,108]. Issues related to
immune hypersensitivity using this approach must ultimately be
addressed, perhaps by ‘‘humanizing’’ the potential antibody
carrier, in order to use these conjugates repeatedly. Clearly,
non-invasive methods based on using endogenous BBB shuttling
compounds for the introduction of therapeutic compounds across
the BBB and into brain parenchyma should be developed as
therapeutic intervention in many neuropathologies may only then
be achieved.
Melanotransferrin (p97) is one such endogenous shuttling
protein that has clear potential as BBB drug delivery vehicle. It
appears to offer many advantages over existing delivery molecules
or systems. First, p97 is a protein found at low levels (,10 ng/mL)
[54] in the blood of most normal individuals. Alzheimer’s patients
appear to be the lone exception identified to date, where levels in
the blood may be two or more fold higher [44,54,109]. Therefore,
inhibition of injected p97-drug conjugates by endogenous material
that could competitively occupy receptors at the BBB appears to
be minimal. Secondly, since the p97 appears to traverse the BBB
as part of its normal function, its use in delivering drugs is not
likely to result in p97-associated toxicity, though this has yet to be
proven in a clinical setting. Thirdly, exogenously-introduced p97
can be expected to localize in concert with the tissue distribution of
the target receptor. Thus it appears to localize to brain
microvasculature and subsequently concentrates in brain paren-
chyma [52]. Therapies for neurological diseases can thereby be
preferentially targeted to the brain. Fourthly, because it is an
autologous human protein, repeated treatments are unlikely to
result in immune hypersensitivity or in elimination by neutralizing
antibodies in clinical therapies. Finally, the transport of p97 and
p97-conjugates does not appear to be adversely affected by the
antiport activities of pumps such as Pgp-1.
This study demonstrates the unique potential of using p97, as a
‘Trojan horse’ to ferry normally excluded therapeutic compounds,
through the battlements of the BBB, thereby allowing forbidden
cargo to traverse from the blood and emerge in the brain. The
utilization of p97 as a shuttling platform is thus a new paradigm
for carrier-mediated transport into the brain. New avenues should
now be open to explore the generalized use of p97 to transport
therapeutic compounds into the brain for the treatment of a
variety of chronic and acute CNS diseases.
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